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Queueing theory model of pentose
phosphate pathway
Sylwester M. Kloska1*, Krzysztof Pałczyński2, Tomasz Marciniak2, Tomasz Talaśka2,
Marissa Miller3, Beata J. Wysocki4, Paul Davis4 & Tadeusz A. Wysocki2,3*
Due to its role in maintaining the proper functioning of the cell, the pentose phosphate pathway (PPP)
is one of the most important metabolic pathways. It is responsible for regulating the concentration of
simple sugars and provides precursors for the synthesis of amino acids and nucleotides. In addition,
it plays a critical role in maintaining an adequate level of NADPH, which is necessary for the cell to
fight oxidative stress. These reasons prompted the authors to develop a computational model, based
on queueing theory, capable of simulating changes in PPP metabolites’ concentrations. The model
has been validated with empirical data from tumor cells. The obtained results prove the stability and
accuracy of the model. By applying queueing theory, this model can be further expanded to include
successive metabolic pathways. The use of the model may accelerate research on new drugs, reduce
drug costs, and reduce the reliance on laboratory animals necessary for this type of research on which
new methods are tested.
In recent years, there has been significant progress in metabolomics. New and improved test methods allow for
the measurement of many important biochemical parameters. The acquired data can be used to create simulation models of biochemical reactions and entire metabolic pathways. Queueing theory can successfully model
metabolic processes, as demonstrated by the example of the glycolysis pathway1 and Krebs cycle2. The preparation
of an accurate model simulating the course of PPP could potentially reduce the time needed for drug testing and
reduce the number of laboratory animals on which new drugs are t ested3.
The PPP is a metabolic pathway whose main substrate is glucose-6-phosphate (G6P). Throughout the reactions that make up this pathway, numerous molecules are formed, such as: nicotinamide adenine dinucleotide
phosphate (NADPH), which is used in the biosynthesis of fatty acids, ribose 5-phosphate (R5P), which is a
precursor in the synthesis of nucleotides, and erythrose 4-phosphate (E4P), which is used in the synthesis of
aromatic amino a cids4,5. Products of the PPP are essential for the formation of new cells. However, under stress,
cell growth is slows down and the PPP is responsible for maintaining cellular levels of NADPH. In fact, such conditions increase the reliance of the PPP in the cell over glycolysis to maintain the needed ratio between NADP+
and NADPH6. In most living organisms, this pathway takes place in the cell cytosol.
There are two phases in the PPP: the oxidative phase and the non-oxidative phase. During the oxidative phase,
NADPH is p
 roduced7. In the non-oxidative phase, various simple sugars are synthesized. 5-carbon sugars derived
from the digestion of nucleic acids can be utilized in the PPP, where their carbon backbones are metabolized into
intermediates for glycolysis or gluconeogenesis. In the non-oxidative phase, one of the enzymes- transketolase—is
responsible for catalyzing two different reactions, with two sets of substrates. Therefore, these substrates act as
inhibitors to each other, since they are competing for the same active site of the enzyme.
It is estimated that as much as 60% of NADPH comes from the PPP8. The PPP is most active in the liver,
adrenal cortex, and mammary glands. The activity for this pathway is high in red blood cells, making it extremely
important in e rythrocytes9. NADPH formed by the PPP is used in the cell to prevent oxidative stress and the formation of dangerous free radicals that could harm the cell10. Reactive oxygen species (ROS) can damage cellular
lipids, proteins, and nucleic acids, and eventually cause cell d
 eath11. It is worth noting that ROS are associated
with many d
 iseases12–14. Since erythrocytes do not have mitochondria, they have no other source of reducing
oxidative stress other than the PPP. For example, large amounts of NADPH generated in erythrocytes are used
to reduce glutathione (GSH). This reduced form of GSH is essential for maintaining the proper state of the cell.
If GSH level is lowered in erythrocytes, hemolysis may occur15.
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Metabolite

Initial conc.
(literature)

Final conc. (model)

Standard deviation
over mean (%)

Absolute difference

Relative difference
(%)
0

Glucose-6-P (G6P)

0.0026

0.0026

3

0

NADP+

0.001

0.001

3

0

0

NADPH

0.0002

0.0002

3

0

0

6-P-gluconolactone
(PGL)

5 × 10−6

9.3 × 10−6

4.3 × 10−6

86

36

6-P-gluconate (6PG)

0.018

0.019

2

0.001

5.5

Ribulose-5-P (Ru5P)

0.012

0.012

2

0

0

Ribose-5-P (R5P)

0.009

0.009

1

0

0

Xylulose-5-P (X5P)

0.018

0.018

1

0

0

Glyceraldehyde-3-P
(G3P)

0.00234

0.00242

3

0.00008

3.4

Sedoheptulose-7-P
(S7P)

0.068

0.062

1

0.006

8.8

Erythrose-4-P (E4P)

0.004

0.004

3

0

0

Fructose-6-P (F6P)

0.083

0.079

0

0.004

4.8

Table 1.  Comparison of concentration data: literature and model (mmol/L). Calculated relative difference
shows similarity of obtained results and literature data.

The most common approach used to model metabolic changes in a cell is to use Ordinary Differential Equations (ODE). For metabolic reactions, ODEs provide quantitative information on interactions that occur between
metabolites in specific reactions taking place in the cell. Previously, ODEs have been successfully used in simulation studies of biochemical kinetics and biochemical connections16–18. The authors in19 presented a PPP model
based on ODEs. This approach was beneficial because it did not require complicated operations that strained
the capabilities of computers in the past, resulting in lower computing power. However, the simplifications
and assumptions made when using ODEs in metabolic simulations do not reflect the stochastic nature of cell
biochemistry20. The Chemical Master Equation (CME) was another approach used to model the stochasticity of
biological reactions21. However, due to the complexity and computing requirements, networks based on these
models cannot be too extensive. A relatively new approach to computational metabolic modeling is the use
of queueing theory. Queueing theory has wide applications in telecommunications, but also in biological and
medical science topics, such as modeling drug pharmacokinetics22 or HIV infectivity23. Using this method, it
was possible to accurately model a simple metabolic network and mimic the interactions between m
 etabolites24,
2
as well as the Krebs c ycle . A genetic algorithm was used to optimize the kinetic coefficients. A variety of AI
methods can be used for this purpose, but genetic algorithm was chosen because it was used with success when
modeling the Krebs cycle.
The aim of this work was to prepare a PPP model capable of tracking concentration changes of specific
metabolites occurring in this pathway over time. Additionally, the usefulness of the genetic algorithm for finding
values of the kinetic constants used in the model was confirmed2. A genetic algorithm was used to find values
corresponding to those in the literature.

Results

The generated model becomes stable within approximately one hour. Every second, there are 1000 simulations
of each pathway reaction (or 1 simulation step per millisecond), averaged over 50 simulated cells. This number
has been selected experimentally. However, the model is designed to vary this number depending on the needs
of the researcher. Figure 1 shows concentration changes of individual metabolites over time. Due to the various
conditions of the living cell, G6P and NADP are consumed faster or slower depending on the blood glucose level,
since glucose is phosphorylated to G6P to stay inside the cell and prevent diffusion out of the cell. This affects the
glucose level in the cell, so the variation of 10% was assumed. The variation level is an arbitrary choice; meaning
it can be changed. The purpose for the use of variation is to represent the concentration fluctuations in the cell.
For this model to reflect the flow of metabolites in the cell as accurately as possible, the so-called “balancing
flow” was u
 sed1,2. This feature allows for proper simulation of metabolite flow depending on the current needs
of the cell (Fig. 2). Thus, the level of metabolites that occur in more than one metabolic pathway, e.g. F6P and
G3P being part of the PPP and glycolysis, better mimics biological conditions. Table 1 presents the comparison
of model generated data and literature data regarding concentration of individual metabolites.
PGL is rapidly hydrolyzed, so the practical equilibrium between G6P and 6PG is directed towards the formation of 6PG25. Any existing PGL is almost immediately converted to 6PG, therefore the variance is very high.
The relative difference of PGL is high because it depends on the measurement time. In the future, we intend to
combine the PPP with the already developed Krebs cycle and glycolysis models, so the results of the PPP model
are likely to be closer to the experimental results.
Due to the high demand of glucose and its metabolites by cancer cells, many drugs are aimed at blocking
metabolic pathways that supply cancer cells with substances necessary for proliferation. The PPP is one of the
pathways with significantly increased activity in neoplastic cells. Compared to healthy cells, the activity of the PPP

Scientific Reports |
Vol:.(1234567890)

(2022) 12:4601 |

https://doi.org/10.1038/s41598-022-08463-y

2

www.nature.com/scientificreports/

Figure 1.  Concentration level change over time under unperturbed conditions. G6P glucose-6-phosphate,
NADP NADP+, PGL 6-P-gluconolactone, 6PG 6-phosphogluconate, Ru5P ribulose-5-phosphate, R5P ribose-5phosphate, X5P xylulose-5-phosphate, G3P glyceraldehyde-3-phosphate, S7P sedoheptulose-7-phosphate, E4P
erythrose-4-phosphate, F6P fructose-6-phosphate.

Figure 2.  PPP scheme; the graph shows the main carbohydrate products, their relations with other
metabolic pathways, and enzymes that catalyze reactions. G6PD glucose-6-phosphate dehydrogenase, PGLS
6-phosphogluconolactonase, PGD 6-phosphogluconate dehydrogenase, RPIA ribose-5-phosphate isomerase A,
RPE ribulose-5-phosphate-3-epimerase, TA transaldolase, TK transketolase.
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Figure 3.  The effects of GPD gene expression knockdown on PGL concentration26. The X axis presents level of
simulated GPD inhibition. The Y axis presents fold change in concentration in comparison to the natural state
(without inhibition).

Figure 4.  The effects of GPD gene expression knockdown on 6PG concentration26. The X axis presents level of
simulated GPD inhibition. The Y axis presents fold change in concentration in comparison to the natural state
(without inhibition).

in cancer cells can be increased up to 8 times. The oxidative part of the pathway provides cells with a large amount
of NADPH, helping the cell can effectively fight excess oxidative stress. Effects that reduce the effectiveness of
the production of NADPH in the cell, in combination with factors that induce this stress, such as radiotherapy
or chemotherapy, can kill cancer cells.
To validate the model, model results were compared to those obtained empirically. The paper26 serving as
the benchmark for our model described the effect of a third PPP enzyme, PGD, in lung cancer cells. Inhibition
of this enzyme’s activity does not significantly affect the level of NADPH, but inhibits tumor growth. The gene
encoding PGD is characterized by increased expression in neoplastic cells. ShRNA molecules were used to reduce
PGD expression. This approach resulted in inhibition of tumor growth , indicating an important role for PGD
in cancer cell metabolism. Concentrations of several PPP metabolites were measured, however, not all of them
had significant changes. Metabolites of the oxidative phase of the PPP, such as 6-phosphogluconolactone (PGL)
and 6-phosphogluconate (6PG) had concentrations 7.9 and 11 times higher than their regular concentrations,
respectively (Figs. 3 and 4). These metabolites accumulated due to the absence/decreased activity of PGD. The
concentrations of metabolites of the non-oxidative phase of the pathway such as S7P or X5P were not measured,
but no significant changes in the concentrations of ribose phosphate and nucleotide triphosphate were detected.
The accumulation of metabolites preceding the blocked reaction is because the expression of the PGD enzyme
has been reduced. A bottleneck is created at this stage of the pathway, leading to a reduced efficiency of this stage,
as there are not enough protein molecules in the cell to process all metabolite molecules. As a further consequence, a decrease in the concentration of metabolites occurring further down the pathway, e.g., G3P, can be
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Figure 5.  The effects of GPD gene expression knockdown on G3P concentration26. The X axis presents level of
simulated GPD inhibition. The Y axis presents fold change in concentration in comparison to the natural state
(without inhibition).

Metabolite

Experimental data
concentration change26

Model data concentration
change using 90% inhibition

Model data concentration
change using 95% inhibition

Model data concentration
change using 98% inhibition

Model data concentration
change using 100% inhibition

G6P

1.8

1.8

1.8

1.8

1.8

PGL

7.9

4.83

5.24

6.08

7.89

6PG

1

G3P

− 3.8

9.59

11.88

14.56

− 1.85

− 2.63

− 3.85

21.8
− 14.29

Table 2.  Comparison of metabolite concentration changes (fold changes) caused by knockdown of the PGD
gene.

observed (Fig. 5). For the validation of the model, measurements of the concentrations of metabolites obtained
empirically were used. The model makes it possible to simulate and track the changes in the concentrations of
the metabolites.
Several measurements were performed to evaluate the level of inhibition of the GPD catalyzed reaction. The
obtained results show that the GPD knockdown caused inhibition at the level of 95–98%. These assumptions
are based on the results presented in Table 2. The results for these inhibition levels are the closest to the empirical results. The paper26 used shRNA to achieve expression knockdown, which is an incomplete mechanism to
reduce (but not eliminate) expression. This form of knockdown is not expected to achieve 100% silencing.
Indeed, 80–99% knockdown of expression is normal and expected. The calculated results are comparable to
those obtained experimentally and are consistent with current biological knowledge. Another point to consider
is that the glucose metabolism of neoplastic cells remains unknown in some aspects and these cells may possibly
bypass a blocked reaction in the metabolic pathway. Simulations using 100% inhibition were also performed,
but this led to a significant reduction in the concentration of metabolites downstream of the bottleneck of the
pathway. However, it can be observed that due to the bidirectional character of reactions of the second phase of
the PPP and the flux of metabolites from other pathways, e.g., F6P generated in glycolysis, we do not observe a
complete ‘zeroing’ of metabolite concentration.
The results generated in our model (Table 2) follows the trend of changes in concentration observed in vitro,
and suggests that knockdown efficiency in vitro was likely near 95%, which is common for shRNA expression
knockdown.

Discussion

As mentioned in the introduction, most previous models simulating metabolic pathways, not only PPP, have
been based on the use of ODEs. However, due to the advantages offered by queueing theory, it seems reasonable
to use this method in modeling. The preparation of a quantitative model of a biological pathway such as the PPP
requires the necessary information on starting concentrations and kinetic data of the enzymes that catalyze the
pathway reactions. The presented model can be viewed as a ’virtual laboratory’. This model tracks the relationships between individual metabolites formed at different stages of the pathway. It is possible to observe changes
caused by fluctuations in metabolite concentrations and their impact on the entire pathway.
It can also be used to test the effectiveness of new drugs if their influence on the kinetics of the reaction
they affect is known. In this way, one can also theoretically get answers to questions such as which reactions are
worth blocking to obtain the best possible therapeutic result. Most studies aimed at blocking the PPP pathway
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Number

Reaction

Enzyme

1

G6P + NADP + −
→ PGL + NADPH + H +

Glucose 6-phosphate dehydrogenase

2

PGL + H2 O −
→ 6PG + H +

6-Phosphogluconolactonase

3

6PG + NADP + −
→ Ru5P + NADPH + H + + CO2

6-Phosphogluconate dehydrogenase

4A

Ru5P −
→ R5P

Ribose-5-phosphate isomerase

4B

Ru5P −
→ X5P

Ribulose 5-phosphate 3-epimerase

5

R5P + X5P −
→ G3P + S7P

Transketolase

6

X5P + E4P −
→ G3P + F6P

Transketolase

7

G3P + S7P −
→ E4P + F6P

Transaldolase

Table 3.  Stoichiometric reactions of the PPP. Reactions 1-3 form the oxidative branch of PPP, reactions 4-7 are
in the non-oxidative branch.

in cancer patients have focused on blocking the first reaction of the pathway catalyzed by G
 6PD27,28. However,
clinical data indicate that this therapy is not very effective without additional exposure to oxidative s tress29,30. For
this reason, the results of studies on the knockdown of the gene encoding PGD in this paper were u
 sed26. Even
though the knockdown of the G6PD gene does not affect the amount of NADPH, which is important for tumor
development, the knockdown of this gene alone results in inhibition of tumor growth. Perhaps the metabolites
that accumulate in the cell prior to the blocked reaction are responsible for this situation. Their concentration
in cells reaches values significantly greater than their natural concentrations. The exact mechanism of tumor
growth inhibition is unknown, however, the effect achieved is important.
The proposed model obtained stability based on the data from the above-mentioned paper. We believe that
this type of model can be used to predict the impact of therapy, which in turn will lead to an increase in its
effectiveness.
Thanks to the use of experimental data together with a computational process based on the queueing theory,
a model was obtained that can track the metabolic pathway that takes place in the cells of living organisms. In
this paper, we present a separate PPP model without detailed analysis of the relationship between PPP and glycolysis. The metabolites common to both pathways have been identified and several principles have been adopted
to create a functional PPP model. In the future, our plan is to connect the existing glycolysis, Krebs cycle, and
PPP models together. We believe that such a procedure may also positively affect the consistency of simulation
and experimental results.
The presented results indicate that the model can be used to predict changes in metabolite concentrations. For
this purpose, it is sufficient to enter the concentration value of one of the metabolites. In this way, the entire study
can prove to be more cost-effective—no need to determine each metabolite separately, which also saves time.
As demonstrated by the knockdown of one of the genes encoding the enzyme catalyzing the PPP reaction,
this model is adapted to follow the trend of metabolite changes. Moreover, it can determine the specific effect of
the inhibition of particular reactions on the concentration of metabolites with relatively high accuracy. Further
research providing data on how inhibition of a particular pathway step may affect kinetic constants could contribute to an increase in the accuracy of the presented model.

Methods

Obtaining metabolic data and the use of enzymatic reaction kinetics. This work focuses on the

reflection of changes in PPP metabolite concentrations over time. For this purpose, a literature review was carried out to provide data on these concentrations (Table 1). Presented concentrations were measured with the
use of mass spectrometry31. Several kinetic constants, and enzymatic properties, like maximum velocity (Vmax ),
necessary for the correct operation of the model were used to calculate the speed of chemical reactions31. Reaction rates were calculated using equations based on Michaelis–Menten kinetics (for more information please
check Supplementary Information).
NADPH is formed from 2 NADP+ molecules in the oxidative phase. The energy generated during the conversion of G6P into ribulose 5-phosphate (Ru5P) is used in the reaction. The overall reaction of the first phase
of the pathway is as follows:

G6P + 2NADP + + H2 O −
→ Ru5P + 2NADPH + 2H + + CO2
Ru5P, which is one of the products of the first phase of the PPP, is the first substrate for the non-oxidative
phase. Ribose-5-phosphate isomerase can convert Ru5P to R5P. On the other hand, ribulose 5-phosphate epimerase converts Ru5P to xylulose 5-phosphate (X5P). The next reactions involve changing the length of the carbon
chain in the carbohydrates. These two five-carbon sugars then undergo a transketolase-catalyzed reaction. The
result is production of glyceraldehyde 3-phosphate (G3P) and sedoheptulose 7-phosphate (S7P). Then G3P and
S7P undergo a transaldolase-catalyzed reaction, which produces E4P and fructose 6-phosphate (F6P) (Fig. 2;
Table 3).

Queueing theory.

The complicated nature of metabolic pathways, in which there are huge amounts of biochemical substances constituting the substrates and reaction products, makes modeling metabolism extremely
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challenging. Methods commonly used to model metabolic pathways require supervision and the use of appropriate constraints, like forcing ODEs not to reach negative values. Such treatments may cause small calculation
errors which could accumulate in long-term modeling and result in incorrect calculations. Biological systems
are organized to pass the products of individual metabolic reactions further down the pathway, so that they
become substrates for downstream reactions or are used by the cell to support necessary life processes32. For this
reason, the use of queueing theory in metabolic pathway modeling seems to be the right approach.
Queueing networks can be thought of as hidden Markov chains, similar to Gillespie’s modelling t echnique20,21.
The advantage of using queueing theory to model metabolic pathways is that they do not require enhanced
computing power. Therefore, the results can be obtained close to real time. Networks based on queueing theory
can be applied with ease to a significantly greater number of molecules, grouped into the queues representing
different molecular species. Due to the nature of this approach, it is capable of combining individual pathways
into larger, more complex groups of metabolic pathways.
Averaging the results from several simulation runs provides information on the average changes in the concentrations of the individual pathway metabolites. The proposed model is based on calculations of the kinetics
of Michaelis–Menten enzymatic reactions, which focus on the relationship between the concentrations of the
substrate and the product, and the velocity of the reaction. According to this theory, the macroscopic concept of
enzymatic reaction speed is the sum of many microscopic reactions that can exchange specific amounts of substances per time unit. The description of the PPP as the probability of decreasing and increasing the concentration
of each of the substances present in the pathway and the correlation of their reduction with the accumulation
of other substrates results in a self-regulating, stochastic process that imitates the actual course of the PPP. The
Michaelis–Menten kinetic equation was used to calculate the probability of the reaction. A detailed description
of the methodology used is described in the work describing the Krebs cycle model2.
The probability of the reaction can be converted to an average amount of arrivals when measured for a significant amount of time. Therefore, the kinetic equations can be used to calculate the adaptive parameter µ(t)
utilized for modelling PPP behavior by a network of inhomogeneous Poisson processes described by equation (1):

P[(N(t + τ ) − N(t)) = k, t] =

e−µ(t)τ (µ(t)τ )k
k!

(1)

Where:

P(N(t + τ ) − N(t)) = k, t]—probability of k arrivals in the interval (t, t + τ )
µ(t)τ —expected number of arrivals in a time interval duration of (t, t + τ )
The queue processing time of metabolite increment is described by the exponential distribution of the random
variable T in the terms of the rate parameter µ(t) as follows (2):

µ(t)e−µ(t)T when T ≥ 0
f (T; µ(t)) =
(2)
0
when dT < 0
Therefore, the PPP is modelled by the composition of interconnected queues. Departure of substrate’s increment
from one queue is followed by the arrival at the successive queue. It is worth noting that the network of interconnected queues is equivalent to the set of ODEs as proven b
 y33.
Probability of substrate’s increment departure from each queue depends on the current concentration of
the substrates and the kinetic constants of the reaction causing that departure. Every queue uses its individual
Michaelis–Menten kinetic equation with kinetic constants normalized according to the method based on the
formula described i n1, to determine the likelihood that in this time step the reaction occurs. Since the reaction
rates depend on the current concentration of molecules that change from step to step, the resulting inhomogeneous Poisson process implements the feedback loop, which results in a system with memory.

Use of a genetic algorithm to optimize model parameters. Values of enzyme kinetic constants were

found with the use of a genetic algorithm starting from literature data. Every ‘gene’ in the ‘chromosome’ is a vector of kinetic constants describing each Michaelis–Menten kinetic equation. The new values of kinetic constants
are found by randomly selecting from which ‘parent’ ‘offspring’ inherits ‘gene’ (set of kinetic constants for a
particular reaction). However, mutation occurs on each kinetic value regardless to which parent it belongs. The
loss function optimized by the algorithm is the sum of the squared distances between PPP state described by the
literature and the current optimization step of the simulation using kinetic constants that makes an individual
‘chromosome’. The formula of loss function is as follows (3):

f (Xl ; X) =
(Xl − X)2
(3)

Where: Xl—vector of substrates described by a literature; X—vector of substrates describing stable state of
simulation.
The loss function described above has a trivial solution. If all kinetic constants that are used in Michaelis–Menten reactions as multipliers (instead of dividers) are zeroed, then the results of these equations are equal
to zero. As a result, no reactions occur, so the simulation’s stable point is equal to the original literature vector.
To prevent such a solution, the genetic algorithm sets a constraint on newly generated ‘chromosomes’. Each
reaction parametrized by values of the ‘chromosome’ for a literature vector of substrates must have a probability
of occurrence between 0.00005 and 0.05.
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The first set of ‘chromosomes’ are made of Michaelis–Menten kinetic constants defined in the literature with
added gaussian noise. Given the selected starting point, the genetic algorithm is set on finding the optimal value
in the proximity of the already established values. This reduces the risk of the algorithm generating an output
that minimizes the loss function, but produces kinetic constants significantly different from the literature values.

Pseudocode of the PPP model.

The pseudocode describing the computational processes can be found in
the Supplementary Information. This code assumes that:

• Kinetic constants are grouped into a table of vectors of constant values. There are 14 vectors in the table
corresponding to eight different reactions and six balancing flows. Each of the reactions has a unique vector of dimension equal to the number of kinetic constants used in the reaction rate computation and every
balancing flow contains a one-dimensional vector.
• Concentration increment exchanged during the reactions is denoted ‘delta’ and is unique for each reaction.
It ranges from 2.3 × 10−6 mM to 5.0 × 10−5 mM. ’Delta’ is significantly lower than the initial value of the
lowest substrate concentration. The ‘delta’ value must be chosen in a way that corresponds to a change of
more than a single molecule for the rare species; in fact, for rare species, it should always be a positive integer
number of molecules.
• the concentrations of G6P and NADP in the cycle vary with 10% Gaussian noise around the constant values
of 0.001 mM and 0.0026 mM, respectively. This signal-to-noise ratio aims to reflect metabolic conditions
inside the cell.
The search for optimal kinetic constants was performed using a PC with AMD Ryzen 7 3800X 8-Core Processor, 3900 MHz, RAM 32 GB. Code was written in C# 8.0. One search epoch simulating one hour for 50 different
tables of kinetic constants using all 8 logic cores, took approximately 7 hours.

Model validation based on the use of experimental data. G6P dehydrogenase is the enzyme that
catalyzes the first reaction of the p
 athway34. Therefore, it is the enzyme that controls the starting velocity of the
pathway. This enzyme is strongly inhibited by N
 ADPH35. Drugs aimed at reducing the intensity of the reaction mainly focus on reducing the activity of this enzyme, which leads to a reduction in the velocity of the
entire pathway27. However, clinical results indicate that inhibiting this enzyme is not an effective therapeutic
approach26. For this reason, data obtained from the study of knockdown expression of the 6-phosphogluconate
dehydrogenase (PGD) enzyme were selected for model validation26.

Data availability

The dataset supporting the conclusions of this article is available in the GitHub repository, https://github.com/
UTP-WTIiE/PPPQueueingTheor y.
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